title: The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension.
abstract: High levels of circulating Von Willebrand factor (vWf) and increased neutrophil to lymphocyte (N/L) ratio may reflect vascular inflammation in hypertensive patients. In present study, we aimed to investigate the effects of valsartan as an angiotensin II receptor antagonist and amlodipine as a calcium channel blocker on the vWf levels and N/L ratio in patients with essential hypertension. Patients were randomized to one of the following intervention protocols: calcium channel blocker (amlodipine, 5-10 mg/day) as group A (n = 20 mean age = 51.85 ± 11.32 y) and angiotensine II receptor blocker (valsartan, 80-320 mg/day) as group B (n = 26 mean age = 49.12 ± 14.12 y). Endothelial dysfunction and vascular inflammation were evaluated with vWf levels and N/L ratio in hypertensive patients before treatment and after treatment in the 12th week. No statistically significant differences were found among the groups in terms of age, sex, and body mass index (BMI). There was a significant decrease in vWf levels (P < .001) and N/L ratio after treatment (P = .04, P < .001, respectively) in both the groups. Von Willebrand factor levels and N/L ratio are very important markers having a role in vascular inflammation and antihypertensive treatment with amlodipine and valsartan may improve cardiovascular outcomes by decreasing these biomarkers.
authors.affiliation: Department of Internal Medicine, Gulhane Medical Academy , Ankara , Turkey.
authors.forename: Murat
authors.initials: M
authors.lastname: Karaman
authors.forename: Sevket
authors.initials: S
authors.lastname: Balta
authors.forename: A Y
authors.initials: AY
authors.lastname: Seyit Ahmet
authors.forename: Mustafa
authors.initials: M
authors.lastname: Cakar
authors.forename: Ilkin
authors.initials: I
authors.lastname: Naharci
authors.forename: Sait
authors.initials: S
authors.lastname: Demirkol
authors.forename: Turgay
authors.initials: T
authors.lastname: Celik
authors.forename: Zekeriya
authors.initials: Z
authors.lastname: Arslan
authors.forename: Omer
authors.initials: O
authors.lastname: Kurt
authors.forename: Necmettin
authors.initials: N
authors.lastname: Kocak
authors.forename: Hakan
authors.initials: H
authors.lastname: Sarlak
authors.forename: Seref
authors.initials: S
authors.lastname: Demirbas
authors.forename: Fatih
authors.initials: F
authors.lastname: Bulucu
authors.forename: Ergun
authors.initials: E
authors.lastname: Bozoglu
mesh_terms: D000328:Adult; D017311:Amlodipine / Q000627:therapeutic use*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D000075222:Essential Hypertension; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy* / Q000503:physiopathology; D007958:Leukocyte Count; D008214:Lymphocytes / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000473:pathology; D011446:Prospective Studies; D013777:Tetrazoles / Q000627:therapeutic use*; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan; D014841:von Willebrand Factor / Q000378:metabolism*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D015415:Biomarkers; D002121:Calcium Channel Blockers; D013777:Tetrazoles; D014841:von Willebrand Factor; D017311:Amlodipine; D000068756:Valsartan; D014633:Valine